Hybio
Hybio Pharmaceutical is a leading peptide-focused CRDMO with over 27 years of R&D and manufacturing experience. The company provides end-to-end support from early research and CMC development to GMP manufacturing and global commercial supply of peptide APIs and finished dosage forms. Hybio’s facilities have passed inspections by major regulatory authorities including FDA, EMA, and NMPA. The company has successfully industrialized and globally supplied complex peptide therapeutics, including injectable and device-combination products, and is actively expanding capabilities in oligonucleotides.
